Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal.

PURPOSE: To determine the efficacy and tolerance of a standardized protocol of chemotherapy and low-dose radiotherapy in the treatment of anal cancer in human immunodeficiency virus (HIV)-infected patients. METHODS AND MATERIALS: Between 1987 and 1995, eight HIV-positive patients with squamous cell carcinoma of the anal canal, four of whom had acquired immunodeficiency syndrome (AIDS), received therapy at the Kaiser Permanente Medical Center. All patients were treated using a combined modality approach consisting of low-dose radiotherapy (30 Gy in 15 fractions delivered 5 days/week), and chemotherapy [1000 mg/m2 of 5-fluorouracil (5-FU) delivered on days 1-4 and 29-32 as a continuous infusion over 96 h, and 10 mg/m2 of mitomycin C delivered as a bolus injection on day 1]. Patients have been followed from 4 to 81 months (mean 41, median 38). RESULTS: All eight patients completed the therapy with minor variations to the protocol, and all have attained a clinical complete response. Four patients are alive and free of disease, and four died as a result of complications of AIDS, but remained free of anal carcinoma. There were no mortalities from the protocol and the morbidity was acceptable. Only one patient each was noted to have Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Grade 4 hematologic and gastrointestinal acute toxicity, and no Grade 4 skin toxicity was noted. CONCLUSION: This combined therapy is effective for HIV-infected patients and appears to be tolerable with acceptable toxicities. It is best applied to patients who are HIV positive, or who have AIDS without concurrent major opportunistic infections. This approach is reasonable and affords patients a reasonably good chance at sphincter preservation by avoiding abdominoperineal resection. The optimal therapy for HIV-positive patients with advanced AIDS remains less well defined.

Risk of incontinence with transurethral resection of the prostate after radiation therapy for prostate cancer.

BACKGROUND: It has been reported that transurethral resection of the prostate (TURP) after definitive radiation therapy for prostate cancer is associated with a significant risk of incontinence. The presumed reason for incontinence is external sphincter damage from TURP or pre-existing damage from either extension of prostate cancer or radiation therapy. METHODS: We reviewed seven recent cases of TURP for bladder outlet obstruction in patients who had undergone radiation therapy for clinical stage T(3-4)M(0)N(0) adenocarcinoma of the prostate. All seven men progressed to either chronic retention or debilitating obstructive symptoms with weak peak flows from 3.4 to 5.1 cc/s (mean 4 cc/s). Each of them subsequently underwent a limited TURP. RESULTS: Voiding symptoms were reduced in all patients and peak flows were improved to 6.3 to 20 cc/s (mean 14.8 cc/s) with mean follow-up 35 m. No patient developed stress urinary incontinence postoperatively. CONCLUSION: These results suggest that TURP can be performed successfully after radiation therapy with minimal risk of stress incontinence.

Massive gastrointestinal hemorrhage from AIDS-related Kaposi's sarcoma confined to the small bowel managed with radiation.

A > 50% incidence of Kaposi's sarcoma (KS) of the gastrointestinal tract has been seen in acquired immunodeficiency syndrome (AIDS) patients with cutaneous KS. Although gastrointestinal Kaposi's sarcoma (GIKS) is usually asymptomatic, hemorrhages from the oral cavity, esophagus, stomach, and large bowel have occurred in this disease. We describe a patient with acute, massive gastrointestinal hemorrhage from GIKS confined to the small bowel who was treated with chemotherapy, surgery, and radiation. To the best of our knowledge, this is the first reported case of AIDS-related GIKS limited to the small bowel. Although chemotherapy is generally used successfully to palliate diffuse GIKS, we report that radiation was an effective modality that rapidly resulted in resolution of considerable local bleeding and could be used in such cases as an alternative to surgery. Details of this case history, including radiographs, are presented.

Cutaneous neuroendocrine (Merkel cell) carcinoma. A report of 35 cases.

Cutaneous neuroendocrine (Merkel cell) cancer (CNEC) is a rare skin tumor with a highly malignant nature. Initial treatment of this tumor has often been limited to a local excision. The medical records of 35 patients diagnosed with CNEC and treated at Southern California Kaiser Permanente Medical Group or UCLA Medical Center between 1980 and 1991 were reviewed. There were 26 male and 9 female patients were enrolled in this study. Minimum follow-up from date of diagnosis was 18 months, mean follow-up was 40 months; 25 patients presented with local disease (stage I) and 10 patients presented with regional disease (involved nodes, stage II). Patients who were treated initially with local therapy alone had a 65% recurrence rate and a 29% mortality rate, while those patients treated locoregionally at presentation had only a 27% recurrence rate and 14% mortality rate, although the majority presented with more advanced disease. Due to the high incidence of lymph node failure and death in patients treated locally versus locoregionally at presentation, we feel that planned locoregional treatment is indicated for all patients presenting with CNEC, regardless of stage.

Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.

PURPOSE: To determine the efficacy of a standardized protocol of chemotherapy and low-dose radiation therapy in treatment of patients with anal canal cancer. MATERIALS AND METHODS: Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C. Survival analysis was performed with the lifetest procedure. RESULTS: In patients with stage T1 and T2 tumors, 26 of 29 (90%) were free of disease after chemotherapy and radiation therapy and had no recurrent tumors. In patients with stage T3 and T4 tumors, five of 13 (38%) were free of disease after therapy and had no recurrences. CONCLUSION: This therapy is effective for epidermoid cancers of the anal canal that are smaller than 5 cm regardless of nodal status. Tumors larger than this or that invade adjacent structures are not adequately controlled with this protocol.

High dose rate intraluminal radiation in a combined modality treatment plan for carcinoma of the esophagus.

We have previously reported results for treatment of adenocarcinomas and squamous cell carcinomas of the mid and distal esophagus as well as the use of intraluminal high-dose rate radiation (HDR-RT) for palliation of carcinoma of the esophagus. In this report we describe the results of a chemotherapy/HDR-RT/esophagectomy management program. Examination of the surgical specimens revealed a complete response in only 13% of patients and locoregional recurrence was disappointing. There were no operative deaths nor were there major complications attributable to the preoperative treatment. Two-year survival was 33%, only slightly better than that previously achieved by us with either primary surgery or primary external beam radiation among "curative" candidates with locoregional disease. HDR in combination with our selected chemotherapy regimen is insufficient for locoregional control and must be supplemented either by esophagectomy or external beam radiation for even modest long-term survival.